Cuban COVID-19 Vaccines To Come Under WHO Scrutiny

Immunization Campaign Begins In Children

The Cuban government has approved the country’s home grown COVID-19 vaccine for emergency use in children, while Mexico is poised to authorize another Cuban vaccine.

Childhood Vaccination
Cuba is vaccinating children as young as two against COVID-19

Cuba has issued emergency use authorizations for two more COVID-19 vaccines, including in pediatric populations as young as two years of age. It has also started the process for obtaining prequalification from the World Health Organization for four COVID-19 vaccines, which would facilitate their use in other countries and could eventually mean large-scale purchases through the Pan American Health Organization (PAHO).

Cuba has forged ahead with COVID-19 vaccine development and regulatory authorities have already issued emergency use authorizations for three of...

More from Approvals

New EU Filings

 

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

 
• By 

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.

More from Product Reviews

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

 

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.

US FDA Requires Opioid Class Labeling Changes Despite Adcomm Advice

 
• By 

Quantitative estimates of the safety risks with opioid pain medication, including the risk of addiction and misuse, must be added to labeling.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.